HK1183015A1 - -氟- -羥基- -吡嗪甲酰胺的鈉鹽 - Google Patents
-氟- -羥基- -吡嗪甲酰胺的鈉鹽Info
- Publication number
- HK1183015A1 HK1183015A1 HK13110207.3A HK13110207A HK1183015A1 HK 1183015 A1 HK1183015 A1 HK 1183015A1 HK 13110207 A HK13110207 A HK 13110207A HK 1183015 A1 HK1183015 A1 HK 1183015A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fluoro
- hydroxy
- sodium salt
- pyrazine carboxamide
- pyrazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010221682 | 2010-09-30 | ||
| PCT/JP2011/072333 WO2012043700A1 (ja) | 2010-09-30 | 2011-09-29 | ６－フルオロ－３－ヒドロキシ－２－ピラジンカルボキサミドのナトリウム塩 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1183015A1 true HK1183015A1 (zh) | 2013-12-13 |
Family
ID=45893139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK13110207.3A HK1183015A1 (zh) | 2010-09-30 | 2013-09-02 | -氟- -羥基- -吡嗪甲酰胺的鈉鹽 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20130274472A1 (zh) |
| EP (1) | EP2623498B1 (zh) |
| JP (1) | JPWO2012043700A1 (zh) |
| CN (1) | CN103209966B (zh) |
| CY (1) | CY1117041T1 (zh) |
| DK (1) | DK2623498T3 (zh) |
| ES (1) | ES2554630T3 (zh) |
| HK (1) | HK1183015A1 (zh) |
| HR (1) | HRP20151263T1 (zh) |
| HU (1) | HUE026872T2 (zh) |
| MY (1) | MY161429A (zh) |
| PH (1) | PH12015501649A1 (zh) |
| PL (1) | PL2623498T3 (zh) |
| PT (1) | PT2623498E (zh) |
| RS (1) | RS54408B1 (zh) |
| SG (1) | SG189161A1 (zh) |
| SI (1) | SI2623498T1 (zh) |
| SM (1) | SMT201600072B (zh) |
| TW (1) | TWI552998B (zh) |
| WO (1) | WO2012043700A1 (zh) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8778398B2 (en) | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| AU2011232408B2 (en) | 2010-03-24 | 2015-07-30 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
| ES2561878T3 (es) * | 2010-09-30 | 2016-03-01 | Toyama Chemical Co., Ltd. | Sal de meglumina de 6-fluoro-3-hidroxi-2-pirazinacarboxamida |
| SG11201504928XA (en) * | 2012-12-22 | 2015-07-30 | Kbp Biosciences Co Ltd | Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor |
| JP6487051B2 (ja) * | 2014-12-30 | 2019-03-20 | サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ | ポリマーナノ粒子の凍結乾燥物、及びその製造方法 |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| WO2018003946A1 (ja) * | 2016-06-30 | 2018-01-04 | 富山化学工業株式会社 | 凍結乾燥製剤の製造方法 |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| US11679083B2 (en) | 2017-12-28 | 2023-06-20 | Fujifilm Toyama Chemical Co., Ltd. | Method for producing freeze-dried formulation |
| CA3115122A1 (en) | 2018-11-19 | 2020-05-28 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
| JP2022522270A (ja) | 2019-03-01 | 2022-04-15 | フラメル アイルランド リミテッド | 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物 |
| CN111249229B (zh) * | 2020-03-10 | 2023-05-02 | 北京阜康仁生物制药科技有限公司 | 一种稳定的法匹拉韦注射液及其制备方法 |
| TR202017792A2 (tr) * | 2020-11-06 | 2021-01-21 | Aroma Ilac Sanayi Ltd Sti | 6-floro-3-hidroksi-2-pirazinkarboksamid etken maddesi veya sodyum tuzunu içeren liyofilizasyon tekniğiyle üretilen yeni bir farmasötik kompozisyon |
| CN112574130B (zh) * | 2020-12-11 | 2021-10-15 | 山东大学 | 一种法匹拉韦药物共晶及其制备方法和应用 |
| CN113750105A (zh) * | 2020-12-11 | 2021-12-07 | 山东大学 | 一种法匹拉韦药用结合物及在制备抗病毒药物制剂中的应用 |
| WO2022131117A1 (ja) | 2020-12-18 | 2022-06-23 | 富士フイルム富山化学株式会社 | 医薬組成物 |
| WO2022131112A1 (ja) | 2020-12-18 | 2022-06-23 | 富士フイルム富山化学株式会社 | 医薬組成物 |
| WO2023033683A1 (ru) * | 2021-09-06 | 2023-03-09 | Общество С Ограниченной Ответственностью "Промомед Рус" | Противовирусная фармацевтическая композиция, содержащая фавипиравир и аминокислоту |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL194097B1 (pl) | 1998-01-07 | 2007-04-30 | Meiji Seika Kaisha | Kompozycja zawierająca krystalograficznie trwałą amorficzną cefalosporynę i sposób jej wytwarzania |
| DE69937405T2 (de) * | 1998-08-20 | 2008-02-14 | Toyama Chemical Co. Ltd. | Stickstoffheterocyclische Carboxamidverbindungen oder deren Salze als antivirale Mittel |
| JP4379767B2 (ja) | 2000-02-16 | 2009-12-09 | 富山化学工業株式会社 | 新規なピラジン誘導体またはその塩、それらを含有する医薬組成物並びにそれらの製造中間体 |
| ZA200905536B (en) | 2007-02-16 | 2010-10-27 | Toyama Chemical Co Ltd | Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination |
| JP2008231064A (ja) | 2007-03-23 | 2008-10-02 | Nippon Shokubai Co Ltd | カルバゾイルアルキル（メタ）アクリレートの製造方法 |
| JP5174365B2 (ja) * | 2007-03-23 | 2013-04-03 | 第一三共株式会社 | キノロン含有凍結乾燥製剤の製造方法 |
| KR101574567B1 (ko) | 2007-09-27 | 2015-12-07 | 토야마 케미칼 컴퍼니 리미티드 | 6-플루오로-3-히드록시-2-피라진카보니트릴의 유기아민염 및 그 제조법 |
| JP5583659B2 (ja) | 2009-03-13 | 2014-09-03 | 富山化学工業株式会社 | ６−フルオロ−３−ヒドロキシ−２−ピラジンカルボキサミド含有錠剤および造粒末 |
| ES2561878T3 (es) | 2010-09-30 | 2016-03-01 | Toyama Chemical Co., Ltd. | Sal de meglumina de 6-fluoro-3-hidroxi-2-pirazinacarboxamida |
-
2011
- 2011-09-29 ES ES11829253.1T patent/ES2554630T3/es active Active
- 2011-09-29 MY MYPI2013001093A patent/MY161429A/en unknown
- 2011-09-29 SG SG2013023437A patent/SG189161A1/en unknown
- 2011-09-29 EP EP11829253.1A patent/EP2623498B1/en active Active
- 2011-09-29 RS RS20150767A patent/RS54408B1/en unknown
- 2011-09-29 PT PT118292531T patent/PT2623498E/pt unknown
- 2011-09-29 JP JP2012536536A patent/JPWO2012043700A1/ja active Pending
- 2011-09-29 US US13/876,998 patent/US20130274472A1/en not_active Abandoned
- 2011-09-29 TW TW100135298A patent/TWI552998B/zh active
- 2011-09-29 SI SI201130722T patent/SI2623498T1/sl unknown
- 2011-09-29 CN CN201180055060.8A patent/CN103209966B/zh active Active
- 2011-09-29 HU HUE11829253A patent/HUE026872T2/en unknown
- 2011-09-29 DK DK11829253.1T patent/DK2623498T3/en active
- 2011-09-29 WO PCT/JP2011/072333 patent/WO2012043700A1/ja active Application Filing
- 2011-09-29 PL PL11829253T patent/PL2623498T3/pl unknown
-
2013
- 2013-09-02 HK HK13110207.3A patent/HK1183015A1/zh unknown
-
2014
- 2014-10-16 US US14/515,673 patent/US9096547B2/en active Active
-
2015
- 2015-06-08 US US14/733,199 patent/US20150266831A1/en not_active Abandoned
- 2015-07-24 PH PH12015501649A patent/PH12015501649A1/en unknown
- 2015-11-24 HR HRP20151263TT patent/HRP20151263T1/hr unknown
- 2015-12-09 CY CY20151101124T patent/CY1117041T1/el unknown
-
2016
- 2016-03-14 SM SM201600072T patent/SMT201600072B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY161429A (en) | 2017-04-14 |
| WO2012043700A1 (ja) | 2012-04-05 |
| ES2554630T3 (es) | 2015-12-22 |
| EP2623498B1 (en) | 2015-11-18 |
| PH12015501649B1 (en) | 2015-10-05 |
| US20150038713A1 (en) | 2015-02-05 |
| US9096547B2 (en) | 2015-08-04 |
| RS54408B1 (en) | 2016-04-28 |
| SG189161A1 (en) | 2013-05-31 |
| EP2623498A1 (en) | 2013-08-07 |
| TW201219375A (en) | 2012-05-16 |
| DK2623498T3 (en) | 2016-02-22 |
| PT2623498E (pt) | 2016-02-02 |
| SI2623498T1 (sl) | 2016-03-31 |
| CN103209966B (zh) | 2015-06-10 |
| HRP20151263T1 (hr) | 2015-12-18 |
| US20130274472A1 (en) | 2013-10-17 |
| JPWO2012043700A1 (ja) | 2014-02-24 |
| SMT201600072B (it) | 2016-04-29 |
| HUE026872T2 (en) | 2016-07-28 |
| TWI552998B (zh) | 2016-10-11 |
| PL2623498T3 (pl) | 2016-05-31 |
| CY1117041T1 (el) | 2017-04-05 |
| EP2623498A4 (en) | 2014-03-26 |
| US20150266831A1 (en) | 2015-09-24 |
| CN103209966A (zh) | 2013-07-17 |
| PH12015501649A1 (en) | 2015-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1183015A1 (zh) | -氟- -羥基- -吡嗪甲酰胺的鈉鹽 | |
| HK1183014A1 (zh) | -氟- -羥基- -吡嗪甲酰胺的葡甲胺鹽 | |
| HK1252424A1 (zh) | 鈉葡萄糖協同轉運蛋白1的抑制劑 | |
| PL2742051T3 (pl) | Amorficzna postać soli sodowej dolutegrawiru | |
| IL237581B (en) | Derivatives of 6-oxo-pyrazinopyrrolopyrimidines | |
| IL232599A (en) | Hydrobromide salt of peridofidine | |
| ZA201308086B (en) | Derivatives of 1-anino-2-cyclopropylboronic acid | |
| ZA201209407B (en) | Modification of xylan | |
| PT2539136T (pt) | Poste de barreira e método de fabrico do mesmo | |
| ZA201302476B (en) | Aluminum salt containing high percentage of al30 | |
| AP3268A (en) | Co-crystals and salts of CCR3-inhibitors | |
| HK1210776A1 (zh) | 取代的 -吡唑- -酚鈉 | |
| GB0906379D0 (en) | Reduced sodium salt | |
| EP2922413A4 (en) | SODIUM SODIUM COMPOSITIONS AND METHOD OF MANUFACTURE AND USE THEREOF | |
| ZA201205320B (en) | Preparation process of the sodium salt of esomeprazole | |
| PT2542591T (pt) | Derivados silílicos de polissacáridos | |
| EP2688426A4 (en) | SALT COMPOSITION WITH REDUCED SODIUM CONTENT | |
| PL2513060T3 (pl) | Krystaliczna postać α karbabenzopirydu | |
| IL243319A0 (en) | Intermediates of teroarylpiperidine and piperazine derivatives | |
| GB2493855B (en) | Reduced sodium salt | |
| HUP1000616A2 (en) | Process for preparation of rosuvastatin salt | |
| HU1000688D0 (en) | Use of trifluoro-phal | |
| GB201216287D0 (en) | Reduced sodium salt |